Big pharmaceutical companies, seeking new pathways in cancer treatment, are increasing investments in antibody drug conjugates (ADCs) developed by biotech firms. BMS recently purchased of an ADC from South Korean biotech Orum Therapeutics for $100m. The development of ADCs involves combining chemotherapies with monoclonal antibodies to specifically target cancer cells, reducing side-effects. ADCs are valued at $9.7bn in 2023 and are expected to double to $19.8bn in five years.
KLAS: Security consulting firms step up as threats rise
In a November 2024 report, KLAS Research identified key healthcare security consulting firms including Tw-Security, Meditology Services, First Health Advisory, Intraprise Health, Fortified Health Security,
